
Cegedim survey updates industry response to aggregate-spending rules
Pharma companies assess their ongoing reporting capabilities
The midnight oil is burning at many pharma companies as they make their final preparations for submitting aggregate-spending data to CMS by March 31, a requirement under the Physicians Sunshine Act. Recent
Cegedim survey data indicate that the reporting tasks are setting up more or less as expected, with pharma companies more easily able to report spending sourced from its sales/marketing activities, and more difficultly for spending sourced from sponsored research. Forty-one percent of manufacturer-respondents are using a third-party IT system to compile their spending data; and 24% are currently using manual or spreadsheet-based processes. Just over half (51%) are using the same system for reporting sample distribution as for spend reporting (depending on the jurisdiction, both of these need to be reported in some cases). Overall, 76% of respondents prefer to have their aggregate-spend solution to include a “pre-integrated customer data solution,” i.e., a
Besides conducting the survey, Cegedim Relationship Management is an active player in they aggregate-spend reporting business, providing both a software platform, AggSpend360, and a master-data service, OneKey, for both national and global healthcare-provider identification. The full report is available, after registration, from Cegedim's site
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.